Get the Stockscreener App
71.82
0.29%
0.21
Halozyme Therapeutics Inc stock is traded at $71.82, with a volume of 2.50M.
It is up +0.29% in the last 24 hours and up +24.82% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$71.61
Open:
$71.62
24h Volume:
2.50M
Relative Volume:
1.17
Market Cap:
$8.40M
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
23.78
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+6.76%
1M Performance:
+24.82%
6M Performance:
+24.36%
1Y Performance:
+16.52%
1-Day Range:
$70.32
$72.09
1-Week Range:
$67.95
$72.33
52-Week Range:
$42.01
$72.33
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
71.82 | 8.07B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-10-25 | Resumed | Goldman | Neutral |
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Halozyme Therapeutics Inc. Enters Reversal Setup in Weekly ChartsPortfolio Return Summary & Consistent Growth Stock Picks - newsyoung.net
Halozyme Therapeutics Shares Jump 1.48% Amid $210M Volume Surge to 463rd U.S. Equities Rank Hits All-Time High as Analysts Raise Price Targets - AInvest
Halozyme Therapeutics Inc. Recovery Linked to Earnings Surprise2025 Key Lessons & Community Trade Idea Sharing - kangso.co.kr
Halozyme Therapeutics stock reaches all-time high at 70.57 USD - Investing.com
H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72 - MSN
Halozyme's Financial Performance and Growth Potential Justify Buy Rating - AInvest
Is now the right time to enter Halozyme Therapeutics Inc.July 2025 Analyst Calls & Accurate Technical Buy Alerts - sundaytimes.kr
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
What is Halozyme Therapeutics Inc.’s book value per shareJuly 2025 Sector Moves & AI Enhanced Market Trend Forecasts - newsimpact.co.kr
Is Halozyme Therapeutics Inc. Starting a New UptrendQuarterly Portfolio Summary & Real-Time Buy Signal Notifications - kangso.co.kr
Halozyme Therapeutics Insider Sold Shares Worth $3,817,389, According to a Recent SEC Filing - MarketScreener
Halozyme’s CEO Helen Torley sells $3.8m in shares By Investing.com - Investing.com Australia
Halozyme’s CEO Helen Torley sells $3.8m in shares - Investing.com India
Halozyme Therapeutics CEO Helen Torley Buys and Sells Shares. - AInvest
HC Wainwright Raises PT to $7 on Biopharma Buy Rating. - AInvest
Recovery Signals Appearing in Halozyme Therapeutics Inc. ChartsEarly Entry Tips With Low Risk Zone Shared - sundaytimes.kr
Halozyme Therapeutics shares rise 1.74% intraday after Acumen Pharmaceuticals reports positive clinical trial updates. - AInvest
What makes Halozyme Therapeutics Inc. stock price move sharplyHigh Performance Equity Ideas - thegnnews.com
Halozyme up after guidance raise, Morgan Stanley upgrade - MSN
Here’s Why Halozyme Therapeutics (HALO) Traded Town in Q2 - Insider Monkey
Halozyme stock price target raised to $56 by Goldman Sachs on IRA impact analysis - Investing.com Canada
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - sharewise.com
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $63.00 at JPMorgan Chase & Co. - MarketBeat
J&J, Halozyme cut at Leerink on price control risk for combo products - MSN
Is Halozyme Therapeutics Inc. part of any ETF3x Gain Trade Candidates - thegnnews.com
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN
Leerink Partners Maintains Sell Rating on Halozyme with $51 Price Target - AInvest
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Why Have Halozyme Stocks Plummeted? - TipRanks
What Does the Market Think About Halozyme Therapeutics? - 富途牛牛
A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $75 to $91 - 富途牛牛
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2025 Earnings Call Transcript - Insider Monkey
Results: Halozyme Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - 富途牛牛
HC Wainwright Raises Price Target for Halozyme Therapeutics to $75 - AInvest
Halozyme raises 2025 revenue guidance to $1.355B amid accelerating royalty growth and new product catalysts - MSN
Halozyme Therapeutics’ Earnings Call Highlights Robust Growth - TipRanks
Halozyme Therapeutics Surges on 86.74% Volume Spike to $360M, 329th Market Activity as Royalty Revenue Drives 41% EBITDA Jump - AInvest
Halozyme Therapeutics 2025 Q2 Earnings Surpasses Expectations, Net Income Surges 77% - AInvest
Halozyme Therapeutics (HALO): A High-Conviction Buy as Royalty-Driven Growth Accelerates - AInvest
Halozyme Therapeutics Lifts Outlook As Royalties Climb Higher - Finimize
HALO: JMP Securities Raises Price Target Despite Maintaining "Ma - GuruFocus
Halozyme (HALO) Surges on Upgraded Guidance and Increased Revenue - GuruFocus
Halozyme up after guidance raise, Morgan Stanley upgrade (HALO) - Seeking Alpha
Halozyme Therapeutics: JMP Securities Raises PT to $91 from $78, Maintains Market Outperform - AInvest
Halozyme Therapeutics Guidance Upgrade Driven by Robust Royalty Revenue, Morgan Stanley Says - MarketScreener
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Halozyme Therapeutics Inc Stock (HALO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Aug 12 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Aug 13 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Aug 13 '25 |
Sale |
64.32 |
20,000 |
1,286,351 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Aug 12 '25 |
Sale |
63.51 |
20,000 |
1,270,121 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Aug 11 '25 |
Sale |
63.05 |
20,000 |
1,260,917 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Jul 08 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Jul 09 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Jul 10 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Jul 10 '25 |
Sale |
57.43 |
20,000 |
1,148,618 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Jul 09 '25 |
Sale |
56.43 |
20,000 |
1,128,655 |
733,719 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):